Plain-English fact sheet
Teduglutide
Also known as Gattex, Revestive, GLP-2 analog
Teduglutide is an intestinal-growth peptide medicine for a narrowly defined short bowel syndrome population, not a general gut-healing or recovery product.
Quick answer
Teduglutide is FDA approved as Gattex for adults and children 1 year and older with short bowel syndrome who depend on parenteral support. It is not approved for routine gut health, inflammatory bowel disease, food intolerance, or wellness.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Teduglutide?
Teduglutide is a long-acting analog of glucagon-like peptide 2, a hormone that supports intestinal growth, blood flow, and absorption.
Its clinical endpoint is reduced need for parenteral nutrition or fluids in short bowel syndrome, not a vague measure of gut repair.
Why are people interested in it?
It is a strong example of a peptide improving organ function through tissue adaptation rather than weight or hormone-release effects.
Its growth-promoting mechanism also explains important polyp, neoplasia, obstruction, and fluid-related safety concerns.
Current regulatory status
Gattex is FDA approved for adults and pediatric patients 1 year of age and older with short bowel syndrome who are dependent on parenteral support.
What is it approved for?
- Treatment of short bowel syndrome with dependence on parenteral support in the age groups specified by the Gattex label
What is it being studied for?
Investigational areas
- Long-term intestinal autonomy and outcomes in selected intestinal-failure populations
Evidence snapshot
Randomized trials support reduced parenteral-support requirements in the labeled population. That evidence does not transfer to general digestive symptoms or unapproved gut-healing claims.
Potential benefits being researched
- Controlled trials found that more participants reduced parenteral-support volume than with placebo.
- Some long-term studies report further support reduction, but response varies and the therapy does not restore normal anatomy.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- The label warns about accelerated neoplastic growth and requires attention to gastrointestinal polyps and malignancy risk.
- Intestinal obstruction, biliary and pancreatic disease, and fluid overload are important labeled risks.
- Increased absorption can change exposure to other oral medicines.
What we still do not know
- Very long-term malignancy and polyp outcomes
- Which patients can achieve durable independence from parenteral support
- How pediatric outcomes evolve across growth and development
- Whether benefits persist after treatment ends
Plain-English takeaway
Teduglutide has a meaningful, narrow intestinal-failure role. Its evidence cannot be repackaged as proof of a general gut-repair peptide.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA prescribing information: Gattex
Current indication, warnings, adverse reactions, and clinical studies.
- 2Randomized teduglutide short bowel syndrome trial
Controlled evidence for reduced parenteral nutrition and fluid requirements.
- 3Phase 3 and extension study in Japan
Small longer-term study illustrating response durability and population limits.